Search

Background Cystic fibrosis (CF) is a chronic disease with an impact on the quality of life. Self-reported symptoms of depression and anxiety were assessed in the Spanish cohort of the International Epidemiological Study on Depression and Anxiety in patients with CF (International Depression-Anxiety Epidemiological Study) and their relationship with health status and health-related quality of life (HRQoL) was evaluated. Methods This cross-sectional study recruited adult patients with CF at 10 Spanish centers. Patients completed the Hospital Anxiety and Depression Scale (HADS) and the Revised Cystic Fibrosis Questionnaire. Demographic and health data were recorded from medical charts. Logistic regression was used to determine the predictors of elevated symptoms of depression and anxiety (HADS ≥ 8). Results Of the 336 participants recruited (mean age, 28.1 years; 48.2% women), 41 (12.2%) had elevated depression-related scores, and 100 (29.7%) had elevated anxiety-related scores (HADS ≥ 8). After adjusting for confounders, only less education, intravenous antibiotics, psychiatric medications and psychotherapy were significantly associated with elevated psychological symptoms. Specifically, regardless of lung function, patients who were depressed or anxious reported worse HRQoL. Conclusions The prevalence of elevated symptoms of depression and anxiety was high in Spanish adult patients with CF, and these symptoms were associated with a decreased HRQoL. [ABSTRACT FROM AUTHOR]

The objective of this study was to analyse lung function decline over time in bronchiectasis, along with the factors associated with it. Spirometry was measured every year in this observational, prospective study in 849 patients from the Spanish Bronchiectasis Registry (RIBRON). The main outcome was the decline in the rate of forced expiratory volume during the first second (FEV1). To be included in this study, patients needed a baseline assessment and at least one subsequent assessment. FEV1 decline was analysed using a mixed-effects linear regression model adjusted for clinically significant variables. We recruited 849 bronchiectasis patients with at least two annual lung function measurements (follow-up range 1–4 years). A total of 2262 lung function tests were performed (mean 2.66 per patient, range 2–5). Mean baseline FEV1 was 1.78 L (standard deviation (SD) 0.76; 71.3% predicted). Mean age was 69.1 (SD 15.4) years; 543 (64% women. The adjusted rates of FEV1 decline were –0.98% predicted/year (95% confidence interval (CI) –2.41 to –0.69) and –31.6 (95% CI –44.4 to –18.8) mL. The annual FEV1 decline was faster in those patients with chronic bronchial infection by Pseudomonas aeruginosa (–1.37% (52.1 mL) vs –0.37% (–24.6 mL); p < 0.001), greater age, increased number of severe exacerbations in the previous year and higher baseline FEV1 value. In patients with bronchiectasis, the annual rate of FEV1 decline was –31.6 mL/year and it was faster in older patients and those with chronic bronchial infection by P. aeruginosa , increased number of previous severe exacerbations and higher baseline FEV1 value. [ABSTRACT FROM AUTHOR]